These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 21658048)

  • 1. Anti-D investigations in individuals expressing weak D Type 1 or weak D Type 2: allo- or autoantibodies?
    Pham BN; Roussel M; Peyrard T; Beolet M; Jan-Lasserre V; Gien D; Ripaux M; Bourgouin S; Kappler-Gratias S; Rouger P; Le Pennec PY
    Transfusion; 2011 Dec; 51(12):2679-85. PubMed ID: 21658048
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular analysis of patients with weak D and serologic analysis of those with anti-D (excluding type 1 and type 2).
    Pham BN; Roussel M; Gien D; Ripaux M; Carine C; Le Pennec PY; Andre-Botte C
    Immunohematology; 2013; 29(2):55-62. PubMed ID: 24094237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allo- and autoanti-D in weak D types and in partial D.
    Flegel WA; Denomme GA
    Transfusion; 2012 Sep; 52(9):2067-9; author reply 2070. PubMed ID: 22946976
    [No Abstract]   [Full Text] [Related]  

  • 4. Anti-D alloimmunization propensity cannot be determined without information on D antigen exposure.
    Yazer MH; Triulzi DJ
    Transfusion; 2012 Sep; 52(9):2069-70; author reply 2070. PubMed ID: 22946977
    [No Abstract]   [Full Text] [Related]  

  • 5. Serological weak D phenotypes: a review and guidance for interpreting the RhD blood type using the RHD genotype.
    Sandler SG; Chen LN; Flegel WA
    Br J Haematol; 2017 Oct; 179(1):10-19. PubMed ID: 28508413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serologic and molecular characterization of D variants in Brazilians: impact for typing and transfusion strategy.
    Credidio DC; Pellegrino J; Castilho L
    Immunohematology; 2011; 27(1):6-11. PubMed ID: 22356480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serologic profiling of D variants in donor routine: unveiling the impact on false-negative results and alloimmunization.
    Arnoni CP; Vendrame TA; Silva FS; Silva NM; Cortez A; Latini F; Castilho L
    Immunohematology; 2024 Jun; 40(2):47-53. PubMed ID: 38910444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combining serology and molecular typing of weak D role in improving D typing strategy in Egypt.
    Abdelrazik AM; Elshafie SM; Ezzat Ahmed GM; Abdelaziz HM
    Transfusion; 2013 Nov; 53(11 Suppl 2):2940-4. PubMed ID: 23362929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-D alloimmunization in Rh(D) negative adults with severe traumatic injury.
    Raval JS; Madden KM; Neal MD; Moore SA
    Transfusion; 2021 Jul; 61 Suppl 1():S144-S149. PubMed ID: 34269429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel weak D types 31 and 32: adsorption-elution-supported D antigen analysis and comparison to prevalent weak D types.
    Körmöczi GF; Förstemann E; Gabriel C; Mayr WR; Schönitzer D; Gassner C
    Transfusion; 2005 Oct; 45(10):1574-80. PubMed ID: 16181207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low incidence of D alloimmunization among patients with a serologic weak D phenotype after D+ transfusion.
    Yazer MH; Brunker PA; Bakdash S; Tobian AA; Triulzi DJ; Earnest V; Harris S; Delaney M
    Transfusion; 2016 Oct; 56(10):2502-2509. PubMed ID: 27401270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How I manage donors and patients with a weak D phenotype.
    Flegel WA
    Curr Opin Hematol; 2006 Nov; 13(6):476-83. PubMed ID: 17053462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transfusion support during childbirth for a woman with anti-U and the
    Yin Q; Srivastava K; Brust DG; Flegel WA
    Immunohematology; 2021 Mar; 37(1):1-4. PubMed ID: 33962485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comprehensive analysis of DEL types: partial DEL individuals are prone to anti-D alloimmunization.
    Körmöczi GF; Gassner C; Shao CP; Uchikawa M; Legler TJ
    Transfusion; 2005 Oct; 45(10):1561-7. PubMed ID: 16181205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Red Blood Cell Antigen Genotyping for Sickle Cell Disease, Thalassemia, and Other Transfusion Complications.
    Fasano RM; Chou ST
    Transfus Med Rev; 2016 Oct; 30(4):197-201. PubMed ID: 27345938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Weak D type 1.1 exemplifies another complexity in weak D genotyping.
    Doescher A; Flegel WA; Petershofen EK; Bauerfeind U; Wagner FF
    Transfusion; 2005 Oct; 45(10):1568-73. PubMed ID: 16181206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prophylactic antigen-matched donor blood for patients with warm autoantibodies: an algorithm for transfusion management.
    Shirey RS; Boyd JS; Parwani AV; Tanz WS; Ness PM; King KE
    Transfusion; 2002 Nov; 42(11):1435-41. PubMed ID: 12421216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Secondary anti-D immunization by Del red blood cells.
    Yasuda H; Ohto H; Sakuma S; Ishikawa Y
    Transfusion; 2005 Oct; 45(10):1581-4. PubMed ID: 16181208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RHD alleles among pregnant women with serologic discrepant weak D phenotypes from a multiethnic population and risk of alloimmunization.
    Bub CB; Aravechia MG; Costa TH; Kutner JM; Castilho L
    J Clin Lab Anal; 2018 Jan; 32(1):. PubMed ID: 28374955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reactivity of FDA-approved anti-D reagents with partial D red blood cells.
    Judd WJ; Moulds M; Schlanser G
    Immunohematology; 2005; 21(4):146-8. PubMed ID: 16472014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.